Clinical Outcomes in Patients With Muscle-Invasive Urothelial Carcinoma Treated With Nivolumab
This retrospective medical record review cohort study of patients with MIUC found clinical outcomes consistent with those observed in the CheckMate 274 trial. These results support the use of adjuvant nivolumab for patient populations in the community, including patients who did not receive NAC. Further research with extended follow-up is needed to elucidate long-term clinical outcomes of adjuvant nivolumab.
Authors
- Taavy A. Miller (ORCID: https://orcid.org/0000-0001-7117-6124)
- Prathamesh Pathak (ORCID: https://orcid.org/0009-0003-6107-4185)
- Sarah Lucht (ORCID: https://orcid.org/0000-0001-5904-2844)
- Xin Yin (ORCID: https://orcid.org/0000-0002-6935-9383)
- M. PATEL (ORCID: https://orcid.org/0000-0002-3543-1420)
- Sarah W. Gordon (ORCID: https://orcid.org/0000-0003-0443-5573)
- Alex Chehrazi‐Raffle (ORCID: https://orcid.org/0000-0001-5205-4527)
- Bruce A. Feinberg (ORCID: https://orcid.org/0000-0001-9267-9994)
- Lisa Rosenblatt
- Regina Barragán-Carrillo (ORCID: https://orcid.org/0000-0002-3114-0642)
- Emily Bland
- William S. John
- Carmelo Alonso
- Hedyeh Ebrahimi
- Andrew J. Klink (ORCID: https://orcid.org/0000-0003-3765-0448)
- Nisha Singh
- JaLyna Laney
Institutions
- Bristol-Myers Squibb (United States) (US)
- City of Hope (US)
- Cardinal Health (United States) (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.14427
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer
- Exelixis
- Cardinal Health